456 related articles for article (PubMed ID: 21520037)
21. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
23. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
Cavazzoni A; Alfieri RR; Cretella D; Saccani F; Ampollini L; Galetti M; Quaini F; Graiani G; Madeddu D; Mozzoni P; Galvani E; La Monica S; Bonelli M; Fumarola C; Mutti A; Carbognani P; Tiseo M; Barocelli E; Petronini PG; Ardizzoni A
Mol Cancer; 2012 Dec; 11():91. PubMed ID: 23234355
[TBL] [Abstract][Full Text] [Related]
24. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
[TBL] [Abstract][Full Text] [Related]
25. A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.
Sato S; Drake AW; Tsuji I; Fan J
PLoS One; 2012; 7(12):e51964. PubMed ID: 23251664
[TBL] [Abstract][Full Text] [Related]
26. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.
Kearns JD; Bukhalid R; Sevecka M; Tan G; Gerami-Moayed N; Werner SL; Kohli N; Burenkova O; Sloss CM; King AM; Fitzgerald JB; Nielsen UB; Wolf BB
Mol Cancer Ther; 2015 Jul; 14(7):1625-36. PubMed ID: 25911688
[TBL] [Abstract][Full Text] [Related]
27. Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway.
Meira DD; Nóbrega I; de Almeida VH; Mororó JS; Cardoso AM; Silva RLA; Albano RM; Ferreira CG
Eur J Cancer; 2009 May; 45(7):1265-1273. PubMed ID: 19167213
[TBL] [Abstract][Full Text] [Related]
28. The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF.
Yoshida T; Okamoto I; Iwasa T; Fukuoka M; Nakagawa K
FEBS Lett; 2008 Dec; 582(30):4125-30. PubMed ID: 19027738
[TBL] [Abstract][Full Text] [Related]
29. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
[TBL] [Abstract][Full Text] [Related]
30. A molecular view of anti-ErbB monoclonal antibody therapy.
Leahy DJ
Cancer Cell; 2008 Apr; 13(4):291-3. PubMed ID: 18394550
[TBL] [Abstract][Full Text] [Related]
31. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
32. GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands.
Lim Y; Yoo J; Kim MS; Hur M; Lee EH; Hur HS; Lee JC; Lee SN; Park TW; Lee K; Chang KH; Kim K; Kang Y; Hong KW; Kim SH; Kim YG; Yoon Y; Nam DH; Yang H; Kim DG; Cho HS; Won J
Mol Cancer Ther; 2016 Feb; 15(2):251-63. PubMed ID: 26586721
[TBL] [Abstract][Full Text] [Related]
33. Multivalent Rhamnose-Modified EGFR-Targeting Nanobody Gains Enhanced Innate Fc Effector Immunity and Overcomes Cetuximab Resistance via Recruitment of Endogenous Antibodies.
Li Y; Lin H; Hong H; Li D; Gong L; Zhao J; Wang Z; Wu Z
Adv Sci (Weinh); 2024 Apr; 11(13):e2307613. PubMed ID: 38286668
[TBL] [Abstract][Full Text] [Related]
34. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
[TBL] [Abstract][Full Text] [Related]
35. BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth.
Boreddy SR; Nair R; Pandey PK; Kuriakose A; Marigowda SB; Dey C; Banerjee A; Kulkarni H; Sagar M; Krishn SR; Rao S; Ar M; Tiwari V; Alke B; Mv PK; Shri M; Dhamne C; Patel S; Sharma P; Periyasamy S; Bhatnagar J; Kuriakose MA; Reddy RB; Suresh A; Sreenivas S; Govindappa N; Moole PR; Bughani U; Tan SL; Nair P
Cancer Res; 2023 Jun; 83(11):1883-1904. PubMed ID: 37074042
[TBL] [Abstract][Full Text] [Related]
36. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.
Quesnelle KM; Grandis JR
Clin Cancer Res; 2011 Sep; 17(18):5935-44. PubMed ID: 21791633
[TBL] [Abstract][Full Text] [Related]
37. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.
Zhou Y; Goenaga AL; Harms BD; Zou H; Lou J; Conrad F; Adams GP; Schoeberl B; Nielsen UB; Marks JD
Mol Cancer Ther; 2012 Jul; 11(7):1467-76. PubMed ID: 22564724
[TBL] [Abstract][Full Text] [Related]
38. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.
Boersma YL; Chao G; Steiner D; Wittrup KD; Plückthun A
J Biol Chem; 2011 Dec; 286(48):41273-41285. PubMed ID: 21979953
[TBL] [Abstract][Full Text] [Related]
39. Expeditious Generation of Biparatopic Common Light Chain Antibodies
Bogen JP; Carrara SC; Fiebig D; Grzeschik J; Hock B; Kolmar H
Front Immunol; 2020; 11():606878. PubMed ID: 33424853
[TBL] [Abstract][Full Text] [Related]
40. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
Schmiedel J; Blaukat A; Li S; Knöchel T; Ferguson KM
Cancer Cell; 2008 Apr; 13(4):365-73. PubMed ID: 18394559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
